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PRMT5‑mediated methylation 
of YBX1 regulates NF‑κB activity 
in colorectal cancer
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The multifunctional protein Y‑box binding protein 1 (YBX1), is a critical regulator of transcription 
and translation, and is widely recognized as an oncogenic driver in several solid tumors, including 
colorectal cancer (CRC). However, very little is known about the upstream or downstream factors 
that underlie YBX1′s regulation and involvement in CRC. Previously, we demonstrated that YBX1 
overexpression correlated with potent activation of nuclear factor κB (NF‑κB), a well‑known 
transcription factor believed to be crucial in CRC progression. Here, we report a novel interaction 
between NF‑κB, YBX1 and protein arginine methyltransferase 5 (PRMT5). Our findings reveal for 
the first time that PRMT5 catalyzes methylation of YBX1 at arginine 205 (YBX1‑R205me2), an event 
that is critical for YBX1‑mediated NF‑κB activation and its downstream target gene expression. 
Importantly, when WT‑YBX1 is overexpressed, this methylation exists under basal (unstimulated) 
conditions and is further augmented upon interleukin‑1β (IL‑1β) stimulation. Mechanistically, 
co‑immunoprecipitation studies reveal that the R205 to alanine (A) mutant of YBX1 (YBX1‑R205A) 
interacted less well with the p65 subunit of NF‑κB and attenuated the DNA binding ability of p65. 
Importantly, overexpression of YBX1‑R205A significantly reduced cell growth, migration and 
anchorage‑independent growth of CRC cells. Collectively, our findings shed important light on the 
regulation of a novel PRMT5/YBX1/NF‑κB axis through PRMT5‑mediated YBX1‑R205 methylation. 
Given the fact that PRMT5, YBX1 and NF‑κB are all among top crucial factors in cancer progression, 
pharmacological disruption of this pivotal axis could serve as the basis for new therapeutics for CRC 
and other PRMT5/YBX1/NF‑κB‑associated cancers.
As part of the family of multifunctional DNA/RNA binding proteins, YBX1 plays critical roles in a wide range of 
cellular functions including transcriptional  regulation1, DNA  repair2,  splicing3, mRNA translation and  stability4 
as well as cellular stress  responses5. Due to its involvement in these important functions, it is unsurprising that 
dysregulation of YBX1 is frequently linked to diseases such as cancer. In fact, its overexpression has been strongly 
associated with certain “hallmark” features such as malignant growth, therapeutic resistance, invasion, metas-
tasis, aberrant cell proliferation and overall poor patient prognosis across several tumor  types6. These include 
but are not limited to cancers of the  breast7,  bladder8,  prostate9 and  colon10, 11. The diverse biological functions 
of YBX1 and its involvement in cancer appear to arise not only from its broad nucleic acid binding properties, 
but may be dependent on its cooperativity with other signaling pathways and molecules responsible for cancer 
development and/or progression. For instance, recent reports indicate that the expression of YBX1 and a Ras 
GTPase-activating protein-binding protein 1 (G3BP1), a protein involved in a variety of growth-related signaling 
pathways, such as p53 and Ras signaling, were highly correlated in  sarcomas12. Moreover, YBX1 was shown to 
directly interact with G3BP1, promoting enhanced migration and invasion of renal cell carcinoma (RCC) cells 
via a Secreted Phosphoprotein 1 (SPP1)/NF-κB signaling  axis12. Intriguingly, our group previously showed that 
YBX1 overexpression could profoundly activate NF-κB signaling, and may thus serve as a novel therapeutic 
target for colorectal cancer (CRC) patients in which aberrant NF-κB activity is a major driver of  malignancy10, 11.
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Over the past decade, constitutive activation of NF-κB has been increasingly recognized as a major player in 
tumorigenesis, cancer progression and the development of chemoresistance in several  cancers13. NF-κB proteins 
represent a family of inducible transcription factors characterized by their ability to orchestrate the expression 
of a large array of genes involved in essential cellular processes such as immune and inflammatory responses, 
differentiation, survival and  proliferation14. The family consists of five proteins [RelA (p65), RelB, c-Rel, p50/
p105 and p52/p100] that are structurally related based on the presence of an N-terminal domain essential for 
dimerization and binding to cognate DNA elements known as the Rel homology domain (RHD)15. In mammals, 
the five NF-κB members typically exist as heterodimers that are retained in the cytoplasm by their interaction 
with inhibitor of NF-κB (IκB)  proteins15. In the context of canonical NF-κB signaling, p65/p50 represents the 
prototypical heterodimeric subunits, and upon stimulation of the cell with certain extracellular signals such as 
stress, cytokines [eg. Interleukin-1 beta (IL-1β)] and Lipopolysaccharides (LPS), IκB becomes proteasomally 
degraded and p65/p50 can then rapidly translocate to the nucleus to activate target gene  transcription16.
Several reports indicate that NF-κB is dynamically regulated by a number of upstream factors, many of which 
help to promote its hyperactivity and tumor-promoting transcriptional  functions13, 17–19. In addition to YBX1, 
we previously showed that the p65 subunit of NF-κB is also positively regulated by another important driver of 
tumor malignancy, protein arginine methyltransferase 5 (PRMT5)10, 11. We found that signal-dependent dimeth-
ylation of R30 of the p65 subunit NF-κB by PRMT5 could profoundly affect the transient binding of NF-κB to 
κB response elements to activate gene  transcription17. PRMT5, a member of the protein arginine methyltrans-
ferase (PRMT) superfamily, catalyzes the symmetric dimethylation of arginine residues on both histones and 
non-histone  proteins20. In general, PRMTs are classified based on the type of methylation marks they catalyze. 
Type I PRMTs (PRMT 1, 2, 3, 4, 6, 8) predominantly catalyze asymmetric dimethylation of arginine residues, 
whereas type II enzymes (PRMT5, 9) mediate symmetrical dimethylation. Type III PRMTs (PRMT7) however 
preferentially catalyze only monomethylation  marks21. PRMT5 is considered the major type II PRMT and func-
tions by interacting with several cytoplasmic and nuclear molecules ranging from transcription factors (eg. p65, 
p53)21, splicing (eg. Sm proteins)22 and elongation factors (eg. Transcription elongation factor SPT50)23, among 
others. Importantly, through these interactions and its frequent overexpression in several tumor types including 
CRC, PRMT5 dysregulation has been linked to tumor cell proliferation, migration, epithelial-to-mesenchymal 
transition (EMT), invasion and  metastasis21. It is therefore unsurprising that an increasing number of studies, 
including ours, have suggested that PRMT5 represents a novel, promising therapeutic anti-cancer  target24. Spe-
cifically, knockdown or small-molecule-mediated PRMT5 inhibition significantly limits the growth of cancer 
cells to improve the overall prognosis of cancer  patients25.
In the present study, we sought to further elucidate the complex molecular underpinnings of a previously 
unreported interaction between PRMT5 and YBX1 and how it relates to NF-κB, with the goal of uncovering 
novel therapeutic avenues for CRC. Previously, our group and others have identified phosphorylation modifica-
tions within the cold-shock domain (CSD) of YBX1 as essential contributors to increasing the complexity of its 
interactions and functional diversity in both normal and malignant cell types. For instance, Evdokimova et al.26 
was the first to demonstrate that Akt-mediated phosphorylation of YB-1(YBX1) at S102 precluded binding 
of YBX1 to mRNA thereby relieving translational repression of oncogenes such as Insulin-like growth factor 
1 (IGF-1), Vascular endothelial growth factor (VEGF) and Fos Proto-Oncogene (FOS) in breast cancer cells. 
More recently, we showed that IL-1β, but not IGF-1, induced the phosphorylation of YBX1 at S165 and S176, 
promoting its cytoplasmic  retention10, 11. We now report for the first time that YBX1 is symmetrically dimethyl-
ated by PRMT5 at the highly conserved arginine 205 (R205) residue, a modification critical to the activation of 
NF-κB by YBX1. Overexpression of an R205A mutant downregulated expression of a subset of NF-κB target 
genes indirectly through attenuation of the DNA binding ability of p65 and YBX1-p65 interaction under both 
basal (unstimulated) and IL-1β-stimulated conditions. Moreover, the migration, anchorage-independent growth 
and cell growth of CRC cells were significantly compromised by overexpression of the R205A mutant compared 
to the wild type YBX1 (WT-YBX1). Our study thus reveals methylation as a novel post-translational modifica-
tion (PTM) on YBX1, and a previously undiscovered functional cooperativity between YBX1 and PRMT5 that 
converges on NF-κB signaling. Together, these findings reveal a new mechanism underlying the finely-tuned 
regulation of specified gene networks involving the activation of a PRMT5/YBX1/NF-κB signaling axis.
Results
YBX1 is symmetrically dimethylated at R205 in response to IL‑1β stimulation. Although 
YBX1 has been widely implicated in promoting cancerous phenotypes, the factors affecting its functions within 
these contexts remain poorly understood. In previous studies, our group and others have shown that YBX1 
can be dynamically regulated by PTMs in cancers of the breast and  colon10, 11, 26. To date, these reports have 
only demonstrated phosphorylation as playing a regulatory role in the translational functions and cellular 
localization of YBX1 in response to certain stimuli such as IGF-1 and more recently by us, IL-1β. However, 
whether other PTMs are involved in modulating additional aspects of its function is still unknown. To deter-
mine whether any additional PTMs exist on YBX1, we first purified Flag-tagged YBX1 using Flag-M2 beads 
from unstimulated and IL-1β-treated HEK293 and subjected the band corresponding to Flag-YBX1 to further 
mass spectrometry analyses. As shown in Fig.  1A (right panel), we found that a peptide with the sequence 
 RPQYSNPPVQGEVMoxEGADNQGAGEQGRPVR (205–234) contained a dimethylation with a mass shift of 
28 Da by the precursor ions of 1089.8540 (3 +) in contrast to 1080.5170 (3 +) of the unmodified peptide. There 
are three Rs in the peptide namely R205, R231, and R234. Further analysis of the fragmented ions indicates 
that the dimethylation is located at the first arginine residue R205, since the series of observed y ions from y3 
to y29 are unaltered in comparison with the unmodified peptides. Furthermore, beside the y series, the mass 
difference of the b series also indicates the modification as occurring on the first R of the peptide. Alignment of 
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YBX1 sequences from different mammalian species showed that this R205 site is located within the disordered 
C-terminal domain and is well conserved (Fig. 1B). Importantly, this R205 dimethylation was observed in both 
IL-1β treated and untreated samples with Flag-tagged WT-YBX1 overexpression.
PRMT5 interacts with and catalyzes symmetric dimethylation of YBX1. To assess the role of 
methylation of YBX1 at R205, we first generated an arginine-to-alanine mutant (R205A) and successfully stably 
overexpressed the R205A mutant at a level comparable with WT-YBX1 in HEK293 and HT29 cells (Fig. 2A). 
Since the mass spectrometry data did not directly inform us of the type of dimethylation (symmetric or asym-
metric), we first identified the potential methyltransferase mediating R205 methylation. Using mass spectrom-
etry protein identification studies, we revealed PRMT5 as a novel interacting partner of YBX1. We then further 
sought to confirm this YBX1-PRMT5 interaction by co-immunoprecipitation followed by western blot analyses. 
Additionally, since PRMT5 catalyzes symmetric dimethyl marks, we also determined whether YBX1 could in 
fact be symmetrically dimethylated. To facilitate this study, we generated the Myc-WT-YBX1 and Myc-R205A 
overexpressing stable cell lines. As shown in Fig. 2B, when Myc tagged-WT-YBX1 was overexpressed, it could be 
symmetrically dimethylated at basal level. However, upon further treatment with IL-1β, the symmetric dimeth-
ylation of the Myc-WT-YBX1 protein immunoprecipitated from HEK293 and HT29 cells was greatly enhanced 
whereas this was abolished on the Myc-R205A mutant protein, indicating that R205 constitutes a major sym-
metric dimethylation site on YBX1. Moreover, co-immunoprecipitation studies confirmed that YBX1 interacted 
more strongly with PRMT5 in response to IL-1β stimulation (Fig. 3A,B) using HEK293 and HT29 cells co-
expressing Flag-PRMT5 and Myc-WT-YBX1 constructs. It is worth noting that even without IL-1β treatment, 
PRMT5 had a certain level of binding with YBX1 at basal level (Fig. 3A,B). Importantly, overexpression and 
shRNA-mediated knockdown of PRMT5 (Fig. 3C) correlated with enhanced and reduced symmetric dimethyla-
tion of YBX1, respectively (Fig. 3D). Furthermore, we observed that both proteins were shown to be localized 
predominantly in the cytoplasm by immunofluorescence experiments with no significantly observable change 
in subcellular distribution upon IL-1β treatment (Fig. 3E). 
R205 methylation is important for the activation of NF‑κB by YBX1 and modulates p65 DNA 
binding ability. Previously, we showed that YBX1 overexpression could significantly augment the activation 
of NF-κB10, 11. We therefore speculated that dimethylated R205 (R205me2) could potentially play an essential 
role in fine-tuning the activation of NF-κB by YBX1. NF-κB-specific luciferase assays were carried out using the 
established cell lines described above. As shown in Fig. 4A, upon IL-1β stimulation, NF-κB transactivation was 
significantly induced in HEK293 and HT29 cells. Overexpression of WT-YBX1 dramatically enhanced this acti-
Figure 1.  Identification of R205 on YBX1 as methylation site (A) Left panel, Tandem mass spectrum of YBX1 
peptide,  RPQYSNPPVQGEVMoxEGADNQGAGEQGRPVR (205–234) with a precursor ion of 1080.5170 (3 +) 
and R205 unmodified (left panel, mass error of 4 ppm) as well as a precursor ion of 1089.8540 (3 +) and R205 
dimethylation (right panel, mass error of − 3 ppm). Mass loss of 64 Da indicates the neutral loss of methionine 
sulfoxide (CH3SOH) from oxidized methionine  (Mox). (B) Domain organization of YBX1 shows Ala/Pro-rich 
N-terminal (A/P) domain (1–55); cold shock domain (CSD, 56–128); disordered C-terminal domain (CTD) 
harboring the conserved Arg 205 (R205) dimethylation residue (129–324).
4
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:15934  | https://doi.org/10.1038/s41598-020-72942-3
www.nature.com/scientificreports/
vation potential, whereas cells with overexpression of the R205A mutant demonstrated significantly less activa-
tion of NF-κB compared with WT-YBX1, suggesting the importance of R205me2 for the complete activation of 
NF-κB by YBX1. We then wondered whether the reduced activation of NF-κB observed with the R205A mutant 
could be indirectly a result of altered protein–protein interactions between p65 and YBX1 and/or impaired 
downstream DNA binding ability of the prototypical p65/p50 heterodimer of NF-κB. To test the first possibil-
ity, we conducted co-immunoprecipitation experiments to compare the extent of the interaction between WT-
YBX1 or R205A and p65. Interestingly, as shown in Fig. 4B, IL-1β-induced interaction between YBX1 and p65 
was attenuated by the R205A mutant. Next, we investigated the DNA-binding capacity of p65 using a κB-specific 
electrophoresis mobility gel shift assay (EMSA). Consistent with our previous reports, overexpression of WT-
YBX1 further enhanced IL-1β-induced κB binding activity of p65, whereas overexpression of the R205A muta-
tion correlated with an impaired DNA binding ability of p65 compared with WT-YBX1 (Fig. 4C). These data 
suggest that R205me2 is necessary for the interaction between YBX1 and p65 and may potentially modulate the 
NF-κB DNA binding ability via this critical protein–protein interaction.
R205 methylation differentially regulates YBX1‑dependent NF‑κB target gene expres‑
sion. Based on our previous findings that overexpression of YBX1 upregulated a discrete subset of NF-κB 
target  genes11, we sought to determine if this also occurs in a methylation-dependent manner. To examine this 
possibility, we conducted an Illumina microarray analysis using HEK293 vector control cells or those overex-
pressing either WT-YBX1 or R205A in the presence and absence of IL-1β for 4 h. We show that among the total 
number of NF-κB target genes in HEK293 vector control cells (genes upregulated twofold or more with IL-1β), 
approximately 53.4% of them could be further upregulated in cells overexpressing WT-YBX1 (Fig. 5A, left pie 
chart), suggesting these are WT-YBX1-dependent NF-κB genes. Importantly, among these genes, ~ 39.4% of 
them were downregulated by at least twofold (R205A/WT-YBX1 ≤ 0.5) (Fig. 5A, upper right pie chart), indicat-
ing that basal levels of R205 methylation is critical for the expression of ~ 39.4% of WT-YBX1-dependent NF-κB 
genes. Similarly, we further analyzed the data in IL-1β-treated WT-YBX1 and R205A samples, and observed that 
approximately 45.8% of WT-YBX1-dependent NF-κB genes were further downregulated twofold or more with 
the R205A overexpression group (lower right pie chart; R205A + IL-1β/WT-YBX1 + IL-1β ≤ 0.5). This represents 
an increase (~ 16.2%) of the WT-YBX1-dependent NF-κB genes that are controlled by R205 dimethylation 
when IL-1β-stimulated. Interestingly but unsurprisingly, cross-comparison of the basal and IL-1β conditions 
for R205A-downregulated genes revealed that approximately 84 genes were commonly shared between these 
groups (Fig. 5B), corresponding to the majority, i.e. ~ 80.8% of R205me2 regulated genes under basal (unstimu-
lated) condition, and ~ 69.4% of R205me2 regulated genes under IL-1β stimulation, respectively. Importantly, 
among these genes, as shown in the representative short list in Fig. 5C, we identified several cytokines (Sup-
plementary Fig. 1), chemokines, or adhesion molecules, including tumor necrosis factor (TNF), interleukin 8 
(IL8), chemokine (C-X-C motif) ligand 10 (CXCL10), Selectin E (SELE), that are well recognized to be impli-
cated in modulating tumor-host responses and metastasis. Two of these genes, IL8 and CXCL10 were further 
confirmed by quantitative PCR analysis. These data recapitulated our microarray findings in which WT-YBX1 
overexpression significantly augmented mRNA levels of these two genes whereas R205A had the opposite effect 
in both HEK293 and HT29 cells (Fig. 5D,E). Upon closer analysis of the signature networks associated with this 
subgroup of genes regulated by R205me2 using an ingenuity pathway analysis (IPA), we observed that the “top 
upstream regulators” were related to IL-1β, TNF and NF-κB (Fig. 6A, left panel). Meanwhile, the “top cellular 
functions” were connected to important cellular mechanisms including “cell death and survival”, “cell growth 
Figure 2.  YBX1 is symmetrically dimethylated on R205 in response to IL-1β. (A) Western analysis of 
comparable expression of WT-YBX1 and R205A constructs stably overexpressed in HEK293 and HT29 cells. 
Anti-YBX1 and anti-β-actin images for each cell line were obtained from different immunoblots and developed 
on film at different exposures. (B) Detection of symmetric dimethylarginine (SDMA) on immunoprecipitated 
Myc-WT-YBX1 or Myc-R205A proteins stably expressed in HEK293 (left) and HT29 cells (right). Anti-Myc IP 
images were obtained from the same immunoblots as Anti-SDMA images that were stripped and reprobed for 
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and proliferation” and “cell movement” (Fig. 6A, middle panel). Importantly, among the “top diseases and disor-
ders”, “cancer” emerged as one of the most enriched networks (Fig. 6A, right panel). Interestingly, representative 
networks in Fig. 6B also uncovered NF-κB as a major hub in these networks. Collectively, these data suggest the 
Figure 3.  YBX1 interacts with, and is symmetrically dimethylated by PRMT5. (A) Representative 
co-immunoprecipitation (Co-IP) of Myc-YBX1 and Flag-PRMT5 shows that YBX1 and PRMT5 interact more 
strongly under IL-1β—stimulating conditions in HEK293 and (B) HT29 cells. Anti-Myc IP and Anti-Myc input 
images were obtained from the same blot with the same exposure. Anti-Flag IP images were obtained from 
the same blot that was stripped and reprobed with Anti-Flag antibody and developed at different exposures. 
First two lanes represent empty vector control stable lines compared to second two lanes which represent 
stable lines dually co-expressing Myc-YBX1 and Flag-PRMT5 constructs. Bottom panels, (A) and (B) show 
representative graphs of quantified western blot Myc co-IP images relative to input. (C) Western analysis to 
assess PRMT5 expression levels in cells expressing either Myc-YBX1 alone (Ctrl) or in combination with 
PRMT5 overexpression vector or shRNA-PRMT5 constructs. (D) Western analysis to assess dimethylation 
status of immunoprecipitated Myc-WT-YBX1 in cells with PRMT5 overexpression or its shRNA knockdown 
(shPRMT5), respectively. Anti-SDMA IP and Anti-Myc IP images were obtained from the same blot, stripped 
and reprobed for total Myc but developed at different exposures. Input images were obtained from different 
blots and developed at different exposures. (E) Immunofluorescence showing the localization of Flag-WT-
YBX1 and PRMT5 with and without IL-1β treatment (10 ng/ul). Hoechst was used for nuclear staining. Images 
were taken at 63 × . *p < 0.05 Ratio of Myc-YBX1/Flag-PRMT5 Co-IP vs.YBX1/Flag-PRMT5 Co-IP + IL-1β 
stimulation relative to input. Densitometry analysis was performed using ImageJ software.
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significant role of methylation of YBX1 at R205 in mediating activation of a subset of NF-κB target genes with 
important roles in inflammation, cell survival and cancer. 
R205 methylation is important for the colony formation, cell migration and growth of CRC 
cells associated with overexpression of YBX1. Based on the network cellular functions enriched in 
our IPA described above (Fig. 6), we wondered whether the R205A mutant would attenuate any of the malig-
nant-like phenotypes associated with YBX1 overexpression. Hence, we next examined the effects of the R205A 
mutant on colony formation (anchorage-independent growth), migration and cell growth potential of a panel 
CRC cell lines (HT29, HCT116, DLD-1). As shown in Fig. 7A, overexpression of WT-YBX1 correlated with the 
formation of larger colonies compared with the vector control cells, whereas cells with overexpression of R205A 
showed a significantly reduced colony forming ability compared with WT-YBX1. Furthermore, we observed a 
similar phenomenon in our Boyden Chamber migration experiments in which overexpression of WT-YBX1 
resulted in the migration of a greater number of cells while the R205A mutant significantly attenuated this effect 
(Fig. 7B). Finally, we also observed in our cell growth assays that the WT-YBX1-oeverexpressing CRC cells had 
a greater growth potential compared to the vector controls while the R205A cells showed a significant reduction 
in number compared to WT-YBX1 over a course of 9 days in cell culture (Fig. 7C). Taken together, these data 
strongly argue for a model in which methylation of YBX1 at R205 modulates its tumor-associated functions in 
CRC under basal conditions.
Upregulation of YBX1 and PRMT5 are positively correlated in colorectal adenocarcinoma 
patient samples. CRC is in part characterized by uncontrolled cell growth as a consequence of the coor-
dinated upregulation of certain oncogenic drivers, many of which have served as useful  biomarkers27. In this 
respect, we sought to further analyze whether the upregulated of YBX1 and PRMT5 are positively correlated in 
CRC patient samples. We found that not only is YBX1 upregulated or mutated across a broad spectrum of can-
cers (Supplementary Fig. 2), but its transcript levels (Fig. 8, left panel) are also significantly higher across colo-
rectal adenocarcinoma (COAD) tumors compared to normal tissue counterparts. Using the same The Cancer 
Genome Atlas (TCGA) data, we observed a similar phenomenon for PRMT5 (Fig. 8, right panel). Interestingly, 
we also observed that the expression level of YBX1 (x-axis) and PRMT5 (y-axis) were significantly positively 
correlated in COAD patients, suggesting that this YBX1-PRMT5 correlation could serve as the basis for future 
patient stratification and identification of patients who are likely to benefit from inhibition of YBX1-PRMT5 
cooperativity. The underlying mechanism of this cooperativity is summarized in our hypothetical model in 
Fig. 9.
Figure 4.  R205A attenuates YBX1-mediated NF-κB activation, p65 DNA binding and complex between p65 
and YBX1. (A) NF-κB luciferase assay performed in HEK293 (left) and HT29 (right) cells stably expressing 
the WT-YBX1 or R205A construct with or without 10 ng/ml IL-1β stimulation. Luciferase readings were 
normalized to both protein concentration and internal control β-galactosidase. (B) Co-immunoprecipitation 
of YBX1 and endogenous p65. HEK293 and HT29 cells stably overexpressing Flag-WT-YBX1 or Flag-R205A 
were treated with 10 ng/mL of IL-1β for 1 h or were left untreated. YBX1 primarily complexes with p65 under 
IL-1β stimulation. Anti-p65 and Anti-Flag IP images were obtained from the same blots that were stripped 
and reprobed for total Flag but developed at different exposures. Input images were obtained from different 
blots and developed at different exposures. (C) EMSA to determine DNA binding ability of p65 performed 
with extracts from HEK293 cells overexpressing WT-YBX1 or R205A. Cells were left untreated or stimulated 
with 10 ng/ml IL-1β for 30mins. The data represent the means ± SD from three independent experiments. 
†p < 0.05 vs. Control (Ctrl) group; *p < 0.05 vs. Ctrl + IL-1β group; §p < 0.05 vs. WT-YBX1 group; **p < 0.05 vs. 
WT-YBX1 + IL-1β group.
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Figure 5.  Loss of methylation on R205A results in differential expression of a subset of YBX1-regulated NF-κB 
target genes. (A) Pie chart, left, representing comparative analysis of the fraction of genes from vector control 
(Ctrl) upregulated two-fold or more by IL-1β and within this group, another 53.4% were further augmented by 
overexpression of WT-YBX1 relative to vector control (WT-YBX1/Ctrl ≥ 2). This group of genes represents the 
WT-YBX1-dependent NF-κB target genes. Pie chart, upper right, shows fraction of WT-YBX1-upregulated genes 
from the left pie chart that were downregulated two-fold or more by R205A overexpression (39.4%) (R205A/
WT-YBX1 ≤ 0.5), representing the genes that are regulated by R205A under basal condition. Similarly, lower right pie 
chart shows fraction of WT-YBX1-upregulated genes from the left pie chart that were downregulated two-fold or more 
by R205A overexpression under IL-1β stimulated condition (~ 45.8%) (R205A + IL-1β/WT-YBX1 + IL-1β ≤ 0.5). (B) 
Venn diagram, shows 84 genes (black font) commonly regulated by basal (R205A/WT-YBX1) and IL-1β-stimulated 
(R205A + IL-1β/WT-YBX1 + IL-1β) groups, corresponding to 80.8% of genes under basal condition (blue font) or 
69.4% of genes under IL-1β stimulated condition (red font), respectively. Each group also had its own pool of solely 
regulated genes, such as 20 genes (19.2%) of basal condition (blue font) and 37 genes (30.6%) of IL-1β-stimulated 
condition, respectively. (C) A representative short list of typical IL-1β-inducible NF-κB target genes upregulated by 
WT-YBX1 but not by R205A under the basal or IL-1β-stimulated conditions. (C) Quantitative PCR (qPCR) analysis 
showing confirmation of two genes from microarray data set. Pro-inflammatory chemokines IL8 and CXCL10 showed 
reduced gene expression in the mutant R205A as compared to that of WT-YBX1 in HEK293 and (D) HT29 cell lines 
under basal and IL-1β-stimulated conditions. The data represent the means ± SD from at least three independent 
experiments. *p < 0.05 vs. Ctrl + IL-1β group; #p < 0.05 vs. WT-YBX1 + IL-1β group.
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Discussion
The findings outlined in this work constitute the first report of methylation of YBX1. We have demonstrated 
that PRMT5-mediated methylation of YBX1 at R205 plays an essential role in the regulation of a subgroup of 
YBX1-dependent NF-κB target genes under both basal (unstimulated) (~ 39.4% of those genes, Fig. 5A), and 
IL-1β stimulated conditions (~ 45.8% of those genes, Fig. 5A). The R205 methylation of YBX1 is important for 
Figure 6.  Ingenious pathway analysis (IPA) of genes regulated by R205 methylation and their associated 
networks and functions. (A) Ingenious pathway analysis (IPA), showing list of upstream regulators (IL-
1β, TNF and NF-κ) as well as top network cellular functions associated with R205 methylation such as cell 
death, survival, proliferation and movement (left and middle panel, respectively). The right panel shows that 
the genes regulated by R205 methylation are associated with networks linked to diseases such as cancer and 
inflammatory-related disorders. (B) Representative networks reveal NF-κB-related proteins as critical nodes in 
these networks.
Figure 7.  R205A attenuates anchorage-independent growth, migration and proliferation of CRC cells. (A) 
Anchorage-independent growth assays performed in CRC cell lines with vector Ctrl, WT-YBX1 or mutant 
R205A. Right panel shows quantified data. (B) Boyden Chamber cell migration assays performed with same 
cells as above. Right panel shows quantified data. (C) Cell growth assay performed in a panel of CRC cell 
lines expressing vector Ctrl, WT-YBX1 or mutant R205A. Cell number was assessed at different days over a 
time course of 9 days. The data represent the means ± SEM or S.D. for at least three independent experiments. 
*p < 0.05 vs. Ctrl. #p < 0.05 vs. WT-YBX1.
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its interaction with p65, revealing a novel cooperativity between YBX1 and PRMT5 that dynamically modulates 
NF-κB activity and target gene expression to render a tumor-promoting effect in CRC cells. Moreover, our dis-
covery that the expression levels of these two tumor-associated proteins are positively correlated in CRC patients’ 
samples is novel and noteworthy. Both YBX1 and PRMT5 have emerged as important therapeutic targets for 
several cancers including CRC and are thought to act upstream of cellular signaling pathways involved in tumo-
rigenesis and cancer  progression21, 28. PRMT5 in particular has especially garnered increasing attention lately. Its 
methylation of arginine residues on both histone and nonhistone proteins has been intrinsically linked to many 
cellular processes to which YBX1 has also been linked such as differentiation, signal transduction, splicing, and 
cell cycle  progression21, 28. Importantly, similar to YBX1, PRMT5 is frequently overexpressed in CRC and other 
human cancers, and its expression is positively correlated with disease progression and poor patient  outcomes25, 
29. Hence, this newly discovered PRMT5/YBX1 axis may potentially serve as an important biomarker and basis 
for patient stratification. Future studies toward elucidating the potential therapeutic benefit of inhibiting both 
YBX1 and PRMT5 will be of great importance in this respect.
Besides the above-discussed aspects, the interaction between PRMT5, YBX1 and NF-κB is likely more com-
plex and exquisite than what our data have captured so far. For instance, we previously reported that PRMT5 
interacts with and can also symmetrically dimethylate the R30 residue of p65, an event that is also triggered by 
IL-1β17, 30. In the current work, we have modeled YBX1 as one target protein of PRMT5 in a similar context, 
however, this model may not present a full picture of what PRMT5 will do in the presence of multiple substrates 
simultaneously. Hence, based on our previous reports, it is likely that both YBX1 and p65 are coordinately meth-
ylated by PRMT5 in our system. One could also speculate that IL-1β may act as a tool to enhance the assembly 
of a larger protein complex in which PRMT5 is brought into close proximity with YBX1, in turn allowing for its 
R205 methylation and association with p65. Meanwhile, PRMT5 could also methylate p65 at R30, which together 
with the YBX1-R205me2-mediated activation of p65, serves the dual purpose of amplifying the NF-κB response. 
These are important questions that require further experimental investigation. Importantly, addressing these 
points will also allow us to better understand one outstanding question in the field. What are the factors that 
Figure 8.  YBX1 and PRMT5 are highly amplified and are significantly correlated in CRC patient samples. (A) 
Box-whisker plots showing transcript levels of YBX1 (left panel) and PRMT5 (right panel) across colorectal 
adenocarcinoma (COAD) tumors and normal based on individual cancer stages. Individual cancer stages 
were based on AJCC (American Joint Committee on Cancer) pathologic tumor stage information and samples 
were divided into stage I, stage II, stage III and stage IV group. Courtesy of UALCAN web-portal, publicly 
available at https ://ualca n.path.uab.edu. (B) Scatter plot showing the expression level of YBX1 (x-axis) and 
PRMT5 (y-axis). Each dot represents log-transformed fragments per kilobase of transcript per million mapped 
reads (FPKM) for individual samples. To obtain data, 459 TCGA colorectal adenocarcinoma tumor samples 
was queried from cBioPortal using R package CGDS-R (https ://cran.r-proje ct.org/web/packa ges/cgdsr ). The 
Pearson correlation was conducted between PRMT5 and YBX1 to detect how much two genes are related. The 
above analyses were conducted in statistical environment R v3.6 and p value less than 0.05 was considered as 
statistically significant, and Bonferroni correction is used in place of multiple-comparison.  R2 = 0.04868.
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govern PRMT5 substrate specificity? Given the complexity of PRMT5 interactions and its multiple nonhistone 
substrates, fully characterizing these factors and understanding their link to observed cancer-associated effects 
will be of paramount importance as we seek to understand the functions of PRMT5 and the consequences of 
its inhibition.
In addition to deciphering the afore-mentioned points, we also acknowledge that the exact mechanism by 
which YBX1, and particularly methylated YBX1 may enhance NF-κB DNA-binding ability is still unknown. Raj 
et al.31 have shown preliminary evidence that YBX1 may potentially modulate p65 transactivation by augment-
ing its affinity for consensus κB sequences. In the present study, we have now confirmed by EMSA that YBX1-
mediated enhancement of this p65 DNA binding occurs in a YBX1 methylation-dependent manner. However, 
how this occurs remains unclear. As suggested by Lorton et al.32, the overall main effect of arginine methylation 
is alteration of protein–protein, protein-DNA, and protein-RNA interactions of the methylated protein. This is 
predicted to be the consequence of new van der Waals contacts that stabilize intra-protein interactions which 
may indirectly increase the affinity of the methylated protein to nucleic  acids17. With regards to the current study, 
these findings are intriguing on many levels. First, YBX1 binds both DNA and RNA and we have now shown 
that its interaction with p65 depends on methylation at R205, implying that methylation of YBX1 at R205 may 
potentially affect some of the cellular and biochemical properties of YBX1 previously assigned to residues in 
the vicinity of the methylated residue. Second, this coincides with data from other groups showing that indeed, 
the C-terminal region of YBX1, where the R205me2 residue is located, is also primarily responsible for the 
sequence-nonspecific binding of YBX1 to DNA and RNA and mediation of protein–protein  interactions33. It 
would therefore be of immense interest to understand how methylation of YBX1 may play a role in not only 
facilitating the YBX1/p65 interaction but whether it may also concomitantly enhance the efficiency of p65 
binding at its consensus DNA sequences based on the indiscriminate but cooperative binding of YBX1 to DNA 
structures near the κB binding sites.
Furthermore, based on previous reports of PRMT5′s and YBX1′s roles in splicing, our discovery may also have 
novel implications for these proteins’ collaborative regulation of the splicing machinery and/or splicing  products4, 
22. More in-depth explorations to address these notions by determining where and how PRMT5, YBX1 and p65 
interact (in the cytoplasm, nucleus, and spliceosome) are warranted. We anticipate that techniques such as cell 
fractionation-immunoprecipitation, chromatin immunoprecipitation (ChIP) and in silico modeling coupled 
with iCLIP-seq analyses will be valuable approaches in this regard.
Finally, since YBX1 has also been shown to synergistically interact with other transcription factors (TFs), 
including AP-134,  p532 and  Smad335 it would be worth investigating if R205me2 serves as a general PTM mecha-
nism for regulating the interaction between YBX1 and these TFs or if this might be a p65-specific phenomenon. 
This knowledge will also unquestionably deepen our understanding of how a single PTM event on YBX1 or how 
possible crosstalk with other TF-PTM circuits can direct the transcription of a specific set of target genes. Fully 
Figure 9.  Hypothetical model of differential effects of R205 methylation of YBX1 on NF-κB signaling and 
promotion of cancer phenotypes. Left side: Under basal conditions (without IL-1β stimulation), overexpression 
of WT-YBX1 activates NF-κB (10, 11) (Figs. 4 and 5). YBX1 is dimethylated on R205, and this is critical for 
the regulation of a substantial subgroup (~ 39.4%) of WT-YBX1-dependent NF-κB genes. Right side: On the 
other hand, in the presence of stimuli such as IL-1β, the IκB kinase phosphorylates IκBα, causing degradation 
of IκB. The liberated p65/p50 heterodimer then migrates to the nucleus to bind to cognate κB sequences on 
the promoters of specific genes, leading to their transcription. While this is occurring, IL-1β can also enhance 
PRMT5-mediated dimethylation of YBX1 at R205 and simultaneously, dimethylation of p65 at R30 based on 
previous findings. These two modifications may serve dual purposes. One, the R205me2 modification serves 
the purpose of enhancing the interaction between p65 and YBX1 and in turn YBX1-mediated activation of p65. 
Second, methylation of p65 by PRMT5, also serves the function of enhancing the activity and together with 
YBX1, positively modulates the overall DNA binding capability of p65. These important modifications also 
positively regulate a subset of NF-κB target genes, i.e. YBX1-R205me2-dependent NF-κB genes. Altogether, 
the enhanced expression of these genes may act in concert to directly or indirectly promote cancer-related 
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understanding the mechanisms underlying such complex interactions may unravel novel therapeutic avenues 
for CRC and other tumor types.
Methods
Cell lines and transfections. The HEK293C6 (293) cell line was previously  described36. CRC cell lines 
HT29, DLD1 and HCT116 were purchased from ATCC (Manassas, VA) and were cultured in RPMI (Roswell 
Park Memorial Institute) 1640 medium supplemented with 100 units/ml penicillin, 100 g/ml streptomycin, and 
5% fetal bovine serum (FBS). The Myc- or Flag-R205A mutant of YBX1 was generated using the QuikChange 
II XL Site-Directed Mutagenesis Kit from Agilent Technologies. Primers were designed using the Agilent Tech-
nologies QuikChange Primer Design online software. Constructs were transfected into HEK293C6 and CRC 
cell lines as essentially described by Lu et al.36 using Lipofectamine and PLUS reagents (Life Technologies/Inv-
itrogen).
Digestion and liquid chromatography‑tandem mass spectrometric analysis. A Coomassie-
stained SDS-PAGE gel band containing the YBX1 protein was subjected to in-gel tryptic digestion as previ-
ously  described36. Following destaining procedures (50% acetonitrile in 100 mm ammonium bicarbonate and 
100% acetonitrile), cysteine residues were reduced using 20 mm DTT at room temperature for 60 min. Alkyla-
tion of the sample was then performed with 55 mm iodoacetamide, 30 min in the dark. Gel pieces were then 
washed with 100 mm ammonium bicarbonate, dehydrated in acetonitrile and dried in a SpeedVac centrifuge. 
Trypsin (Promega, WI) was used to rehydrate and digest the sample, overnight at 37  °C. Extracted peptides 
were reconstituted in 0.1% formic acid and prepared for mass spectrometry analysis. Proteolytic digests were 
analyzed using an LTQ Orbitrap XL linear ion-trap mass spectrometer (Thermo Fisher Scientific) coupled with 
an Ultimate 3000 HPLC system (Dionex). The data were analyzed by Mascot software (Matrix Science) against 
customized YBX1 protein database with the setting of 10 ppm for precursor ions and 0.8 Da for product ions. 
The tandem mass spectra of candidate-modified peptides were further interpreted manually.
Western blotting and antibodies. Cells were cultured to about 90–95% confluence before treatment 
with IL-1β (10 ng/ml). Whole cell samples were collected and lysed using Radio Immunoprecipitation Assay 
buffer (RIPA buffer: 150 mM NaCl, 0.1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate 
(SDS), 50 mM Tris–HCl pH 8.0 and protease inhibitors)36. Whole cell lysates were then separated by SDS/PAGE 
gels, and further assessed by Western blotting. Different antibodies were used to detect the target proteins of 
interest, obtained from the following commercial sources: anti-YBX1 (Abcam, ab12148) anti-PRMT5 (Abcam, 
ab109451), anti-Flag (Sigma-Aldrich, F1804), anti-Myc (Cell Signaling, 71D10) and anti-p65 (Santa Cruz Bio-
technology, sc-109).
Luciferase assays. NF-κB luciferase assays were conducted as previously  described36. Briefly, lentivi-
rus made from the κB-luciferase construct p5XIP10 κB, envelope plasmid pMD2.G and packaging plasmid 
pCMV8.91 was used to infect vector control, Flag-WT-YBX1 or Flag-R205A stable cell lines after which lucif-
erase activity was quantified 48 h later using the Luciferase Assay System with Reporter Lysis Buffer kit (Pro-
mega). The κB-luciferase plasmid p5XIP10  κB contains five tandem copies of the NF-κB DNA binding site 
derived from the IP10 gene (an established target gene of NF-κB) upstream of a luciferase reporter gene. Lucif-
erase activity was measured using a Synergy H1 Multi-Mode Reader (BioTek Instruments Inc.).
Co‑immunoprecipitations. Cells were cultured to 95% confluency then lysed in co-immunoprecipitation 
buffer (1% Triton X-100 (v/v), 50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM sodium orthova-
nadate, 20 μM aprotinin, 1 mM phenylmethanesulfonyl fluoride, and 1 mM pepstatin A). The Flag or Myc-YBX1 
proteins were immunoprecipitated with anti-Flag-M2 beads (Sigma-Aldrich, A2220) or anti-Myc-beads (Sigma, 
E6654), using immunoprecipitation methods previously described. Briefly, cell lysates with equivalent amounts 
of protein were incubated with appropriate beads at 4 °C overnight. Beads were then washed and tagged proteins 
were eluted and separated by SDS/PAGE.
Cell growth and anchorage‑independent growth assays. For cell growth assays, vector ctrl or CRC 
cells overexpressing Flag-WT-YBX1 or R205A constructs were seeded in triplicate at 2 × 104 cells/well in a 6-well 
plate. Cells were counted at days 3, 5, 7 and 9 post-seeding using a cell counting chamber. For anchorage-
independent growth assays, type VII agarose (Sigma) was used to prepare 2.4% and 1.2% bottom and top agar 
layers, respectively. 2 × 105 cells were resuspended in the top layer and plated onto the bottom layer. Cells were 
then cultured for 12–14 days at 37 °C and 5% CO2. Images of colonies were captured using a Canon EOS Rebel 
T3i Digital SLR camera and colony size and number were quantified using ImageJ (https ://image j.nih.gov/ij/).
Migration assay. Migration assays were conducted using Boyden chambers. Briefly, a Boyden chamber 
consists of 8 μm pore size cell culture inserts in a 24 well plate. Each insert was coated with gelatin on the side 
facing the lower chamber. 2 × 105 cells were seeded in the top of the insert (upper chamber) in serum-free media 
while serum-rich media (10% serum) was supplied in the well below as a chemoattractant. After 48 h, migrated 
cells were fixed with 4% formaldehyde and stained with crystal violet. Stained cells were visualized with a light 
microscope and quantified. Images were captured using a Canon EOS Rebel T3i Digital SLR camera.
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Immunofluorescence assay. Immunofluorescence assays were carried out as previously  described11. 
1 × 105 HEK293 cells overexpressing Flag-WT-YBX1 were seeded in a 24-well plate unto a 0.1% sterile gelatin 
pre-coated coverslip/well and left overnight. Cells were fixed with 4% formaldehyde solution for 30 min followed 
by blocking buffer for 10 min at R.T. Coverslips were further probed with anti-Flag antibody for the detection of 
Flag-tagged WT-YBX1 and anti-PRMT5 antibody for the detection of endogenous PRMT5 followed by Alexa 
Fluor 488 (green) goat anti-mouse IgG and Alexa Fluor 594 goat anti-rabbit IgG. Coverslips were sealed using 
mounting media containing HOECHST to stain the nucleus. All slides were visualized under a Leica DMI6000B 
series fluorescent microscope at 63 × magnification.
Illumina microarrays and quantitative PCR (qPCR). Microarray and qPCR experiments were carried 
out as essentially described by Wei et al.17. Briefly, cells were cultured to ~ 90% confluence and total RNA was 
isolated using Trizol reagent. Total isolated RNA was used to prepare cDNA using the SuperScript III First-
Strand Synthesis PCR System (Invitrogen). cDNA was labeled with biotin-UTP using the Illumina Total Prep 
RNA amplification kit (Ambion/Applied Biosystems, Foster City, CA), hybridized to Illumina Human Ref-v3 
v1 Expression Bead Chips and then scanned in a Bead Array reader using standard Illumina protocols (Illu-
mina, San Diego, CA). Illumina’s Bead Studio software was used for data analysis. qPCR was carried out using 
FastStart Universal SYBR Green Master ROX (Roche). Primers were designed by the Primer Express 3.0 soft-
ware. Primer information is listed below: CXCL10-Forward: 5′- TGA AAA AGA AGG GTG AGA AGA GAT G-3′; 
CXCL10-Reverse: 5′-CCT TTC CTT GCT AAC TGC TTT CAG -3′; IL8-Forward: 5′-TCC TGA TTT CTG CAG CTC 
TGT-3′; IL8-Reverse: 5′-AAA TTT GGG GTG GAA AGG TT-3′.
Cytokine array. The human cytokine ELISA array was purchased from Signosis, Inc. (Santa Clara, CA 
USA). Experiments were carried out according to the manufacturer’s protocol. Briefly, cells from HT29 con-
trol, WT-YBX1- and R205A—overexpressing stable cell lines were seeded and cultured for 72 h. Conditioned 
media from these cells was collected by centrifugation and added to specific cytokine capture antibody precoated 
wells for 2 h at R.T. Wells were then washed the luminescent signals were detected using an HRP luminescent 
substrate and Synergy H1 Multi-Mode Reader (BioTek Instruments Inc.). The luminescent signal emitted cor-
responded to the relative level of expression for each specific cytokine detected.
Ingenuity pathway analysis (IPA). Groups of genes regulated by R205A were analyzed by the IPA 
 software11. The setting and filter were as follows: reference set: Ingenuity Knowledge Base (Genes _ Endogenous 
Chemicals); Relationship to include: Direct and Indirect; Includes Endogenous Chemicals; Filter Summary: 
Consider only molecules where species _ Human OR Rat OR Mouse. The p values for the enrichment test were 
calculated using Fisher’s exact test, right-tailed. Log10 (p) was visualized to the left of the p value. p < 0.05 was 
considered to be statistically significant.
Correlation analyses. The RNA-seq for 459 TCGA colorectal adenocarcinoma tumor samples was queried 
from cBioPortal using R package CGDS-R (https ://cran.r-proje ct.org/web/packa ges/cgdsr /). The gene expres-
sion data was then log transformed and used for correlation analysis between YBX1 and PRMT5. The Pearson 
correlation was conducted between genes to detect how much they are related. The above analyses were con-
ducted in statistical environment R v3.6 and p value less than 0.05 was considered as statistically significant, and 
Bonferroni correction is used in place of multiple-comparison.
Statistical analysis. Statistical analyses were performed using Prism 6 software (GraphPad, San Diego, 
CA). Data represent the mean ± S.D. or SEM as indicated. A two-tailed Student’s t-test was used when comparing 
two means between groups as specified. All statistics were carried out for triplicate experiments and a p < 0.05 
was considered statistically significant.
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